AR and cancer: Regrettably, CRPC eventually develops resistance to enzalutamide due to a combination of mechanisms, such as intratumoural androgen synthesis, the overexpression and gain-of-function mutations of the AR gene, the expression of AR splice variants, the activation of Wnt signalling, and the Warburg effect associated with altered cancer cell metabolism [6, 39, 54].